SciELO - Scientific Electronic Library Online

 
vol.146 número10Presentación atípica de neoplasia pulmonar: lesiones quísticas pulmonares “no siempre benignas” índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

SANCHEZ, CESAR et al. Survival of patients with advanced HER2+ breast cancer. Analysis of a cancer center database. Rev. méd. Chile [online]. 2018, vol.146, n.10, pp.1095-1101. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872018001001095.

HER2+ breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies.

Aim:

To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades.

Material and Methods:

Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2,149 of 2,724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease.

Results:

Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p = 0.09).

Conclusions:

A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies.

Palabras clave : Breast Neoplasms; Survival; Trastuzumab.

        · texto en Español     · Español ( pdf )